Pith. sign in

REVIEW 4 major objections 6 minor 78 references

medicX-KG: A Knowledge Graph for Pharmacists' Drug Information Needs

T0 review · 4 major / 6 minor · reviewed 2026-08-15 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗ Review JSON

Pith's one-line read The paper claims that medicX-KG, a knowledge graph merging Malta's medicines registry with BNF and DrugBank, can fully answer pharmacist queries about drug availability, drug-drug interactions, adverse reactions, and therapeutic classes.

desk verdict A real, honestly-built Malta-specific drug knowledge graph whose abstract overclaims on the strength of seven hand-picked competency questions. read the letter →

arxiv 2506.17959 v1 pith:BMUEDQTV submitted 2025-06-22 cs.AI

Lizzy Farrugia , Lilian M. Azzopardi , Jeremy Debattista , Charlie Abela This is my paper · ORCID
classification cs.AI
keywords KnowledgeGraphsPharmacistDecisionSupportDrug-DrugInteractionsRegulatoryInformationSystemsMedicinesAvailabilityOntologyMappingMaltaCompetencyQuestions
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

Pharmacists in Malta, and similar small jurisdictions, must consult several uncoordinated sources to answer basic drug questions because no unified national repository exists. This paper claims that a single knowledge graph, medicX-KG, can close that gap by merging the Maltese Medicines Authority product list, the British National Formulary, and DrugBank into one semantic layer. The evaluation reported here shows the graph fully answering queries about product availability, drug-drug interactions, adverse reactions, and therapeutic classes, while dosage queries remain unanswered and indication and pregnancy/breastfeeding questions are only partially answered. The broader claim is that locality-aware knowledge graphs, not general biomedical graphs, are the right infrastructure for pharmacist-facing decision support in regulated, small-market settings. A sympathetic reader would take the contribution to be the demonstration that this integration is feasible and useful, with the mapping pipeline as the core scientific work.

What carries the argument

The load-bearing mechanism is the ontology combined with a multistage rule-based entity mapping pipeline. The ontology's classes, including Product, ActiveIngredient, DrugDrugInteraction, AdverseDrugReaction, TherapeuticClass, ATC code, and MarketingAuthorisation, let local product records inherit clinical relationships from global sources. The mapping pipeline proceeds from exact name matching to synonym and salt resolution via DrugBank, decomposition of combination products, and PubChem fallback, linking the 9,746 MMA product records to BNF monographs and DrugBank entries while flagging the 303 entities that remain unresolved. This mapping is what turns a list of regulatory approvals into a graph that can answer questions such as which products containing amoxicillin are authorised in Malta and whether warfarin interacts with amlodipine.

What would settle it

Take a random sample of 200 of the 9,746 Maltese product records and have two pharmacists independently map each active ingredient to the BNF and DrugBank entries. If the independent mappings disagree with medicX-KG's mappings often enough to change the answer to CQ2 (availability) or CQ3 (interaction), the Fully Met results rest on mapping accuracy that the paper does not directly measure.

Watch

Extended reading notes

Core claim

medicX-KG is a pharmacist-oriented knowledge graph that integrates Malta's Medicines Authority product registry, BNF clinical content, and DrugBank molecular and pharmacological data. Its central claim is that this harmonised graph supports real-world pharmacist queries about locally authorised products, drug-drug interactions, adverse reactions, and therapeutic classes, with evaluation of seven competency questions yielding Fully Met for those four categories, Partially Met for indications and pregnancy/breastfeeding safety, and Not Met for dosage. The paper presents the graph as the semantic layer of the medicX platform and argues that embedding national regulatory status directly into the schema is what makes it useful in jurisdictions where EMA alignment coexists with UK supply dependence.

Load-bearing premise

The rule-based mapping that links each Maltese product record to its BNF and DrugBank entries is correct and complete enough that a wrong or missing link does not change the answers to availability and interaction queries.

Editorial extensions

If this is right

  • Pharmacists can answer availability checks, interaction checks, ADR lookups, and therapeutic-class queries from one graph, replacing manual reconciliation of BNF, DrugBank, and MMA records.
  • Polypharmacy risk screening becomes expressible as a graph query because drug-drug interactions are modelled as first-class entities with severity and mechanism.
  • The same construction method transfers to other small jurisdictions with split regulatory alignment, provided a national product registry and mapping file are available.
  • The current graph cannot answer dosage queries and gives only partial answers for indications and pregnancy/breastfeeding precautions, so those uses require the planned SmPC posology integration.
  • Without the planned continuous-update pipeline, the static snapshot will drift from current authorisations and interaction knowledge, limiting clinical safety.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • An implication the authors leave implicit is that the mapping pipeline's error profile is the real test of clinical trust: if wrong synonym resolutions are concentrated among commonly prescribed ingredients, availability and interaction answers could be wrong even though aggregate counts look high.
  • A testable extension is to run the same evaluation against a random sample of MMA products with pharmacist-verified mappings, which would separate graph coverage from mapping correctness and could be reported as precision and recall per competency question.
  • The ontology's explicit regulatory entities, such as marketing authorisation, storage, and product form, suggest a reusable locality layer: a different national regulator could supply a mapping file and instantiate its own view, which the authors mention for future work but do not demonstrate.
  • Because the graph's 1.39 million DDI edges largely come from DrugBank and BNF, the local contribution is only as strong as the product-to-ingredient links; a quick audit of interaction answers for the most dispensed Maltese products would show whether the local layer adds value beyond what DrugBank alone provides.
Share X Bluesky LinkedIn Reddit HN

Signed reviews

No signed human review yet.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

4 major / 6 minor

Summary. This paper presents medicX-KG, an RDF knowledge graph that integrates the Malta Medicines Authority product registry, British National Formulary clinical content, and DrugBank pharmacological data through a four-stage rule-based mapping pipeline (direct match, synonym/salt resolution, combination decomposition, and unique identifier assignment). The ontology represents products, active ingredients, indications, contraindications, adverse drug reactions, therapeutic classes, and drug-drug interactions, with explicit source provenance. Design requirements were elicited from six Maltese pharmacists via semi-structured interviews. The evaluation uses seven competency questions (CQ1-CQ7) executed in SPARQL and compared with manual answers for selected drugs; four CQs are reported as fully met (availability, DDI, ADR, therapeutic class), one as not met (dosage), and two as partially met (indication, pregnancy/breastfeeding). The paper positions medicX-KG as a locality-aware knowledge graph for small jurisdictions and discusses limitations including missing dosage encoding, static snapshots, and lack of longitudinal validation.

Significance. If the claims were fully supported, medicX-KG would be a useful transferable blueprint for locality-aware pharmacy knowledge graphs, with a clean separation between regulatory products and pharmacological active ingredients, explicit provenance, and a modular ontology aligned to practical pharmacist queries. The paper's strengths include transparent mapping statistics (Tables 3-5), reproducible code and sample data on GitHub, and a candid statement of limitations, including an explicit note in Appendix E that the evaluation is an 'initial effort' requiring expansion. The qualitative grounding in interviews is a genuine strength. However, the current evidence does not yet establish the abstract's claim that medicX-KG 'effectively supports' the four query families across the registry, because the evaluation covers only a handful of favourable examples and does not measure coverage, precision/recall, or mapping accuracy. The significance is therefore conditional on a substantially stronger evaluation.

major comments (4)
  1. [Appendix E / Table E4 / Section 4.1] The evaluation is too weak to support the abstract claim that medicX-KG 'effectively supports queries about drug availability, interactions, adverse reactions, and therapeutic classes.' Seven CQs are tested on a small set of common drugs (amoxicillin, paracetamol, warfarin/amlodipine/ativan, ibuprofen, metformin, lisinopril, valproate), with no random or stratified sample from the 9,746-product registry, no precision/recall/F1, no inter-annotator agreement, and no empirical comparison against the source systems (BNF, DrugBank, Micromedex). The authors themselves state in Appendix E that the comparison is 'an initial effort' and that 'we still require a more thorough evaluation.' At minimum, the abstract should be recast as reporting feasibility on selected examples, or the evaluation needs to be extended before the current claim can stand.
  2. [Section 3.3.2 / Tables 3-5] The mapping pipeline is the load-bearing component, but its accuracy and completeness are unmeasured. No gold-standard alignment set is provided, so the 'Fully Met' results inherit any mapping errors. The reported gaps are large: 852 MMA components with no BNF match, 468 with no DrugBank match, and 303 unresolved even after PubChem fallback. A locally authorised product whose active ingredient falls into those unmatched sets will silently return empty or partial answers for DDI (CQ3) and ADR (CQ4) queries. The selected test drugs are common, internationally standardised substances and are likely over-represented among successful mappings. The authors should report mapping precision/recall on a manually reviewed random sample and stratify competency-question tests across mapped and unmapped products.
  3. [Appendix E / Table E4] The reported CQ outcomes are internally inconsistent. CQ4 is marked 'Fully Met' although the SPARQL query returns 4 side effects against 5 manual entries, and the note below the table states that matching counts do not automatically imply a fully met outcome. No explanation is given for why a one-item shortfall with a small absolute count still counts as fully met. The same issue affects the interpretation of the other outcomes: without explicit criteria and per-query precision/recall, the binary 'Fully Met / Partially Met / Not Met' labels cannot be independently verified.
  4. [Section 4.2 / Table 9] The comparison against DrugBank, Hetionet, PharmKG, and Micromedex is presented as an evaluation ('empirically validates'), but it is a qualitative feature comparison. No query from Section 4.1 is run against the comparator resources, and the claim of 'precision and semantic richness unmatched by broader KGs or commercial databases' is not supported by any measured result. Please either reframe this section as positioning/qualitative analysis or add a direct head-to-head query evaluation on the same competency questions.
minor comments (6)
  1. [Section 1] In the paragraph beginning 'The national regulatory contexts', 'more 65%' should read 'more than 65%'.
  2. [Tables 3-5] Please clarify whether the counts in successive mapping stages are disjoint or cumulative; for example, whether the 1,226 PubChem matches overlap with the 1,061 DrugBank matches would substantially affect the interpretation of coverage.
  3. [Figure 5] The caption states that the bars correspond to mapping strategies rather than sources; please clarify the axes and whether a single product can be counted in multiple bars.
  4. [Appendix E] The SPARQL queries use the `mdx:` prefix for both ontology classes and instance identifiers; using separate prefixes for the T-Box and A-Box would improve readability.
  5. [Section 3.2.1] The statement that ADRs were 'highlighted by half of the interviewees' is consistent with Table C1 (3/6), but the text would benefit from explicitly citing Table C1 at that point.
  6. [Section 4.2.3] The sentence beginning 'The competency evaluation empirically validates this complementarity' overstates the evidence; please align this wording with the scope of the current evaluation.

Circularity Check

0 steps flagged · score 0.0 of 10

No circularity: medicX-KG is an integration artifact evaluated by standard competency-question retrieval QA, not a derivation or prediction whose output is defined by its inputs.

full rationale

The paper makes no predictive or first-principles derivation claim. medicX-KG is constructed by mapping MMA product records to BNF and DrugBank entries using a multistage rule-based procedure (Section 3.3.2), and the evaluation (Section 4.1, Appendix E) executes seven SPARQL competency questions, comparing retrieved answers to external references such as SmPCs, BNF, and DrugBank. Because those references are also the graph's source data, the evaluation is a retrieval and integration consistency check rather than a fitted parameter renamed as a prediction. The paper does not claim to derive or predict the source content; it claims query support, and the CQ method checks whether the queries return complete, relevant, semantically correct answers. The self-citations (Farrugia and Abela 2020; Farrugia et al 2023) are contextual history and future-work references, not load-bearing justifications of the mapping rules or of the evaluation outcomes. There is no imported uniqueness theorem, no ansatz smuggled via citation, and no renaming of a known result as a new one. Weaknesses such as only seven hand-picked competency questions, absent precision/recall metrics, and the 852/468/303 unmatched mapping entities are evaluation-coverage and correctness-risk concerns, not circularity. The derivation chain—data sources, mapping, graph construction, query evaluation—is self-contained, and the central claim is externally falsifiable by testing the SPARQL queries on a broader sample of the registry. Overall, no significant circularity is present.

Assumptions & free parameters 0 free parameters · 4 assumptions · 0 invented entities

No free parameters are fitted, and no new physical or chemical entities are postulated. The graph's content is derived from three external sources plus mapping heuristics. The main unvalidated assumptions are mapping correctness, source authority, small-sample representativeness, and the completeness of manual reference answers.

assumptions (4)
  • domain assumption BNF, DrugBank, and the Malta Medicines Authority registry are authoritative and accurate for their respective content domains.
    Section 3.3.1 treats these sources as ground truth for clinical and regulatory assertions; the KG inherits any source errors, and no independent validation of source content is reported.
  • ad hoc to paper The rule-based mapping heuristics (direct match, synonym/salt resolution, decomposition) correctly align MMA products and ingredients to BNF and DrugBank entries.
    Section 3.3.2 and Tables 3-5 report mapping counts but no gold-standard validation. Every downstream query result, including the "Fully Met" outcomes, depends on this assumption.
  • domain assumption Six purposively sampled pharmacists' information needs are indicative of Maltese pharmacy practice.
    Section 3.2 states that the sample is small and the results "should be interpreted as indicative rather than representative." The KG schema and query design rest on these interview findings.
  • domain assumption The manually prepared reference answers used to judge SPARQL results are correct and complete.
    Appendix E reports that two annotators judged the answers, but no agreement metric, adjudication procedure, or external clinical reference audit is provided.

how reviews work

0 comments
Cite this review

Pith. "Pith review of medicX-KG: A Knowledge Graph for Pharmacists' Drug Information Needs." pith.science (2026). https://pith.science/paper/BMUEDQTV

@misc{pith2026250617959,
  author       = {Pith},
  title        = {Pith review of: medicX-KG: A Knowledge Graph for Pharmacists' Drug Information Needs},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/BMUEDQTV}},
  note         = {Machine review of arXiv:2506.17959}
}
read the original abstract

The role of pharmacists is evolving from medicine dispensing to delivering comprehensive pharmaceutical services within multidisciplinary healthcare teams. Central to this shift is access to accurate, up-to-date medicinal product information supported by robust data integration. Leveraging artificial intelligence and semantic technologies, Knowledge Graphs (KGs) uncover hidden relationships and enable data-driven decision-making. This paper presents medicX-KG, a pharmacist-oriented knowledge graph supporting clinical and regulatory decisions. It forms the semantic layer of the broader medicX platform, powering predictive and explainable pharmacy services. medicX-KG integrates data from three sources, including, the British National Formulary (BNF), DrugBank, and the Malta Medicines Authority (MMA) that addresses Malta's regulatory landscape and combines European Medicines Agency alignment with partial UK supply dependence. The KG tackles the absence of a unified national drug repository, reducing pharmacists' reliance on fragmented sources. Its design was informed by interviews with practicing pharmacists to ensure real-world applicability. We detail the KG's construction, including data extraction, ontology design, and semantic mapping. Evaluation demonstrates that medicX-KG effectively supports queries about drug availability, interactions, adverse reactions, and therapeutic classes. Limitations, including missing detailed dosage encoding and real-time updates, are discussed alongside directions for future enhancements.

Review history (2 revisions) →

Discussion (0). Continue with ORCID to comment.

Reference graph

Works this paper leans on

78 extracted references · 63 canonical work pages

  1. [1]

    ://www.amcp.org/sites/default/files/2024-04/AMCP-Format-5.0-JMCP-web_0.pdf

    Academy of Managed Care Pharmacy (2024) AMCP Format for Formulary Submissions Version 5.0 . ://www.amcp.org/sites/default/files/2024-04/AMCP-Format-5.0-JMCP-web_0.pdf

    work page 2024

  2. [2]

    Frontiers in Research Metrics and Analytics 6

    Asada M, Gunasekaran N, Miwa M, et al (2021) Representing a Heterogeneous Pharmaceutical Knowledge-Graph with Textual Information . Frontiers in Research Metrics and Analytics 6

    work page 2021

  3. [3]

    JACCP: Journal Of The American College Of Clinical Pharmacy 3(5):973--979

    Azzopardi LM, Serracino-Inglott A (2020) Clinical pharmacy education and practice evolvement in malta. JACCP: Journal Of The American College Of Clinical Pharmacy 3(5):973--979. doi:https://doi.org/10.1002/jac5.1280

    doi:10.1002/jac5.1280 2020

  4. [4]

    Journal of biomedical informatics 41(5):706--716

    Belleau F, Nolin MA, Tourigny N, et al (2008) Bio2RDF : towards a mashup to build bioinformatics knowledge systems. Journal of biomedical informatics 41(5):706--716

    work page 2008

  5. [5]

    arXiv preprint arXiv:240503932 ://arxiv.org/abs/2405.03932

    Bikaun T, Stewart M, Liu W (2024) CleanGraph: Human-in-the-loop Knowledge Graph Refinement and Completion . arXiv preprint arXiv:240503932 ://arxiv.org/abs/2405.03932

    arXiv 2024

  6. [6]

    Nucleic Acids Research 32(Database issue):D267--D270

    Bodenreider O (2004) The Unified Medical Language System ( UMLS ): integrating biomedical terminology. Nucleic Acids Research 32(Database issue):D267--D270. doi:10.1093/nar/gkh061, ://www.nlm.nih.gov/research/umls/

    doi:10.1093/nar/gkh061 2004

  7. [7]

    Briefings in Bioinformatics 23(6):bbac404

    Bonner S, Barrett IP, Ye C, et al (2022) A review of biomedical datasets relating to drug discovery: A knowledge graph perspective. Briefings in Bioinformatics 23(6):bbac404

    work page 2022

  8. [8]

    Qualitative research in psychology 3(2):77--101

    Braun V, Clarke V (2006) Using thematic analysis in psychology. Qualitative research in psychology 3(2):77--101

    work page 2006

Show all 78 references
  1. [9]

    BMJ Group and Pharmaceutical Press, London, UK, ://bnf.nice.org.uk/, accessed April 10, 2025

    British Medical Association , Royal Pharmaceutical Society (2024) British National Formulary (BNF), 88th edn. BMJ Group and Pharmaceutical Press, London, UK, ://bnf.nice.org.uk/, accessed April 10, 2025

    2024

  2. [10]

    Annual Review of Biomedical Data Science 3:23--41

    Callahan TJ, Tripodi IJ, Pielke-Lombardo H, et al (2020) Knowledge-based biomedical data science. Annual Review of Biomedical Data Science 3:23--41. doi:10.1146/annurev-biodatasci-011720-074428, ://doi.org/10.1146/annurev-biodatasci-011720-074428

    2020 doi

  3. [11]

    Scientific Data 10(1):67

    Chandak P, Huang K, Zitnik M (2023) Building a knowledge graph to enable precision medicine. Scientific Data 10(1):67

    2023

  4. [12]

    Medical teacher 45(2):167--178

    Cook DA, Bikkani A, Poterucha Carter MJ (2023) Evaluating education innovations rapidly with build-measure-learn: Applying lean startup to health professions education. Medical teacher 45(2):167--178

    2023

  5. [13]

    Semantic Web ://www.semantic-web-journal.net/content/matcha-dl-tool-supervised-ontology-alignment, submitted February 27, 2024; under review

    Cotovio PG, Ferraz L, Faria D, et al (2024) Matcha-DL: A Tool for Supervised Ontology Alignment . Semantic Web ://www.semantic-web-journal.net/content/matcha-dl-tool-supervised-ontology-alignment, submitted February 27, 2024; under review

    2024

  6. [14]

    ://www.medicines.org.uk/emc, accessed: 2024-04-18

    Datapharm Ltd (2024) Electronic Medicines Compendium (EMC) . ://www.medicines.org.uk/emc, accessed: 2024-04-18

    2024

  7. [15]

    Journal of Decision Systems 28(3):224--232

    Dennehy D, Kasraian L, O’Raghallaigh P, et al (2019) A lean start-up approach for developing minimum viable products in an established company. Journal of Decision Systems 28(3):224--232

    2019

  8. [16]

    ://www.dynamed.com/, accessed: 2024-04-18

    EBSCO Information Services (2024) DynaMed . ://www.dynamed.com/, accessed: 2024-04-18

    2024

  9. [17]

    European Commission (2024) Commission staff working document: Analytical document accompanying the Commission Proposal for a Council Recommendation on stepping up EU actions to combat antimicrobial resistance in a one health approach. Tech. Rep. SWD(2024) 49 final, European Co...

    2024

  10. [18]

    https://www.ema.europa.eu, accessed April 10, 2025

    European Medicines Agency (2024) European Medicines Agency: Scientific Evaluation and Supervision of Medicines . https://www.ema.europa.eu, accessed April 10, 2025

    2024

  11. [19]

    In: Proceedings of the 3rd International Conference on Applications of Intelligent Systems

    Farrugia L, Abela C (2020) Mining Drug-Drug Interactions for Healthcare Professionals . In: Proceedings of the 3rd International Conference on Applications of Intelligent Systems. Association for Computing Machinery, New York, NY, USA, APPIS 2020, doi:10.1145/3378184.3378196

    2020

  12. [20]

    arXiv preprint arXiv:230804172

    Farrugia L, Azzopardi LM, Debattista J, et al (2023) Predicting Drug-Drug Interactions Using Knowledge Graphs . arXiv preprint arXiv:230804172

    2023

  13. [21]

    Nature Communications 13(1):5304

    Fern \'a ndez-Torras A, Duran-Frigola M, Bertoni M, et al (2022) Integrating and formatting biomedical data as pre-calculated knowledge graph embeddings in the Bioteque . Nature Communications 13(1):5304. doi:10.1038/s41467-022-33026-0

    2022 doi

  14. [22]

    (2025) FDB MedKnowledge Clinical Drug Knowledge

    First Databank, Inc. (2025) FDB MedKnowledge Clinical Drug Knowledge . https://www.fdbhealth.com/, accessed April 2025

    2025

  15. [23]

    American Journal of Health-System Pharmacy 78(4):307--316

    Flynn AJ, Fortier C, Maehlen H, et al (2021) A strategic approach to improving pharmacy enterprise automation: Development and initial application of the autonomous pharmacy framework. American Journal of Health-System Pharmacy 78(4):307--316. doi:10.1093/ajhp/zxaa356

    2021 doi

  16. [24]

    ACM Computing Surveys 51(5):93:1--93:42

    Guidotti R, Monreale A, Ruggieri S, et al (2019) A Survey of Methods for Explaining Black Box Models . ACM Computing Surveys 51(5):93:1--93:42. doi:10.1145/3236009

    2019 doi

  17. [25]

    In: Proceedings of the 12th Knowledge Capture Conference 2023, pp 131--139

    Hertling S, Paulheim H (2023) OLaLa : Ontology matching with large language models. In: Proceedings of the 12th Knowledge Capture Conference 2023, pp 131--139

    2023

  18. [26]

    Applied Sciences 12(13):6606

    Hertling S, Paulheim H, Shvaiko P (2022) Benchmarking ontology matching systems: An updated survey. Applied Sciences 12(13):6606. doi:10.3390/app12136606

    2022 doi

  19. [27]

    Elife 6:e26726

    Himmelstein DS, Lizee A, Hessler C, et al (2017) Systematic integration of biomedical knowledge prioritizes drugs for repurposing. Elife 6:e26726

    2017

  20. [28]

    medRxiv doi:10.1101/2023.07.12.23292499, ://doi.org/10.1101/2023.07.12.23292499

    Hou Y, Yeung J, Xu H, et al (2023) From Answers to Insights: Unveiling the Strengths and Limitations of ChatGPT and Biomedical Knowledge Graphs . medRxiv doi:10.1101/2023.07.12.23292499, ://doi.org/10.1101/2023.07.12.23292499

    2023 doi

  21. [29]

    JMIR mHealth and uHealth 10(8):e37290

    Hyzy M, Bond R, Mulvenna M, et al (2022) System Usability Scale Benchmarking for Digital Health Apps: Meta‑analysis . JMIR mHealth and uHealth 10(8):e37290. doi:10.2196/37290

    2022 doi

  22. [30]

    https://www.fip.org/file/5591

    International Pharmaceutical Federation (2023 a ) Ethics and the pharmacist: Privacy and confidentiality. https://www.fip.org/file/5591

    2023

  23. [31]

    ://www.fip.org/file/6065

    International Pharmaceutical Federation (2023 b ) Improving access to safe and quality essential medicines and medical devices: The role of pharmacy. ://www.fip.org/file/6065

    2023

  24. [32]

    https://github.com/gnn4dr/DRKG/

    Ioannidis VN, Song X, Manchanda S, et al (2020) DRKG - drug repurposing knowledge graph for covid-19. https://github.com/gnn4dr/DRKG/

    2020

  25. [33]

    In: The Semantic Web - ISWC 2011, Lecture Notes in Computer Science, vol 7031

    Jiménez-Ruiz E, Grau BC (2011) LogMap : Logic-based and scalable ontology matching. In: The Semantic Web - ISWC 2011, Lecture Notes in Computer Science, vol 7031. Springer, pp 273--288, doi:10.1007/978-3-642-25073-6_18

    2011 doi

  26. [34]

    Data & Knowledge Engineering 105:4--25

    Keet CM, awrynowicz A (2016) Ontology competency questions: A survey, best practices, and proposed CI methodology . Data & Knowledge Engineering 105:4--25. doi:10.1016/j.datak.2016.04.003

    2016 doi

  27. [35]

    Nucleic acids research 52(D1):D1265--D1275

    Knox C, Wilson M, Klinger CM, et al (2024) DrugBank 6.0: the drugbank knowledgebase for 2024. Nucleic acids research 52(D1):D1265--D1275

    2024

  28. [36]

    Nucleic Acids Research 46(D1):D558--D566

    Koleti A, Terryn R, Stathias V, et al (2018) Data Portal for the Library of Integrated Network-based Cellular Signatures (LINCS) program: integrated access to diverse large-scale cellular perturbation response data . Nucleic Acids Research 46(D1):D558--D566. doi:10.1093/nar/gk...

    2018 doi

  29. [37]

    Br J Clin Pharmacol 88(9):4067--4079

    Kontsioti E, Maskell S, Bensalem A, et al (2022) Similarity and consistency assessment of three major online drug-drug interaction resources. Br J Clin Pharmacol 88(9):4067--4079

    2022

  30. [38]

    Nucleic acids research 44(D1):D1075--D1079

    Kuhn M, Letunic I, Jensen LJ, et al (2016) The SIDER database of drugs and side effects. Nucleic acids research 44(D1):D1075--D1079

    2016

  31. [39]

    Frontiers in Bioinformatics 3:1328613

    Le H, Chen R, Harris S, et al (2024) RxNorm for drug name normalization: a case study of prescription opioids in the fda adverse events reporting system. Frontiers in Bioinformatics 3:1328613

    2024

  32. [40]

    Bulletin of the Medical Library Association 88(3):265

    Lipscomb CE (2000) Medical Subject Headings (MeSH) . Bulletin of the Medical Library Association 88(3):265

    2000

  33. [41]

    arXiv preprint arXiv:250206472 ://arxiv.org/abs/2502.06472

    Lu Y, Wang J (2025) KARMA: Leveraging Multi-Agent LLMs for Automated Knowledge Graph Enrichment . arXiv preprint arXiv:250206472 ://arxiv.org/abs/2502.06472

    2025

  34. [42]

    ://medicinesauthority.gov.mt/howmedicinesregistered, accessed: 2025-04-04

    Malta Medicines Authority (2020) How medicines are registered. ://medicinesauthority.gov.mt/howmedicinesregistered, accessed: 2025-04-04

    2020

  35. [43]

    https://medicinesauthority.gov.mt, accessed April 10, 2025

    Malta Medicines Authority (2024) Malta Medicines Authority : Regulatory information and services. https://medicinesauthority.gov.mt, accessed April 10, 2025

    2024

  36. [44]

    BMC geriatrics 17:1--10

    Masnoon N, Shakib S, Kalisch-Ellett L, et al (2017) What is polypharmacy? A systematic review of definitions . BMC geriatrics 17:1--10

    2017

  37. [45]

    BMC bioinformatics 22:1--17

    Masumshah R, Aghdam R, Eslahchi C (2021) A neural network-based method for polypharmacy side effects prediction. BMC bioinformatics 22:1--17

    2021

  38. [46]

    https://www.mayoclinic.org, accessed April 2025

    Mayo Clinic (2023) Mayo Clinic: Reliable health information and tools for patients . https://www.mayoclinic.org, accessed April 2025

    2023

  39. [47]

    ://www.medscape.com/, accessed: 2024-04-18

    Medscape, LLC (2024) Medscape . ://www.medscape.com/, accessed: 2024-04-18

    2024

  40. [48]

    https://www.micromedexsolutions.com/, accessed April 10, 2025

    Merative (2024) Micromedex solutions. https://www.micromedexsolutions.com/, accessed April 10, 2025

    2024

  41. [49]

    Bioinformatics 39(2):btad080

    Morris JH, Soman K, Akbas RE, et al (2023) The scalable precision medicine open knowledge engine (SPOKE): a massive knowledge graph of biomedical information . Bioinformatics 39(2):btad080

    2023

  42. [50]

    Computational and Structural Biotechnology Journal 18:1414--1428

    Nicholson DN, Greene CS (2020) Constructing knowledge graphs and their biomedical applications. Computational and Structural Biotechnology Journal 18:1414--1428. doi:10.1016/j.csbj.2020.05.017, ://doi.org/10.1016/j.csbj.2020.05.017

    2020 doi

  43. [51]

    Information 15(8):509

    Peng C, et al (2023) Knowledge Graphs: Opportunities and Challenges . Information 15(8):509. doi:10.3390/info15080509

    2023 doi

  44. [52]

    Bioinformatics 34(15):2614--2624

    Percha B, Altman RB (2018) A global network of biomedical relationships derived from text . Bioinformatics 34(15):2614--2624

    2018

  45. [53]

    Nucleic acids research 48(D1):D845--D855

    Pi \ n ero J, Ram \' rez-Anguita JM, Sa \"u ch-Pitarch J, et al (2020) The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic acids research 48(D1):D845--D855

    2020

  46. [54]

    Patterns 2(1)

    Reese JT, Unni D, Callahan TJ, et al (2021) KG-COVID-19 : a framework to produce customized knowledge graphs for COVID-19 response. Patterns 2(1)

    2021

  47. [55]

    Briefings in Bioinformatics 23(5):bbac363

    Ren ZH, et al (2022) A biomedical knowledge graph-based method for drug–drug interactions prediction through combining local and global features with deep neural networks. Briefings in Bioinformatics 23(5):bbac363. doi:10.1093/bib/bbac363

    2022 doi

  48. [56]

    Semantic Web 15(3):567--599

    Robaldo L, Batsakis S (2024) On the interplay between validation and inference in SHACL : An investigation on the time ontology. Semantic Web 15(3):567--599. doi:10.3233/SW-240030, early access, published online 2024‑02‑17

    2024 doi

  49. [57]

    International journal of medical informatics 86:54--61

    Romagnoli KM, Boyce RD, Empey PE, et al (2016) Bringing clinical pharmacogenomics information to pharmacists: a qualitative study of information needs and resource requirements. International journal of medical informatics 86:54--61

    2016

  50. [58]

    BMC Medical Informatics and Decision Making 20(4):314

    Rossanez A, dos Reis JC, Torres RdS, et al (2020) KGen : a knowledge graph generator from biomedical scientific literature. BMC Medical Informatics and Decision Making 20(4):314

    2020

  51. [59]

    Sant Fournier MA (2000) Pharmacy and the EU : the impact of european union membership on the pharmacy profession in malta

    2000

  52. [60]

    Drug Safety 38(2):197--206

    Scheife RT, Hines LE, Boyce RD, et al (2015) Consensus Recommendations for Systematic Evaluation of Drug-Drug Interaction Evidence for Clinical Decision Support . Drug Safety 38(2):197--206. doi:10.1007/s40264-014-0262-8

    2015 doi

  53. [61]

    Research in Social and Administrative Pharmacy 18(8):3323--3328

    Shariff A, Sridhar SB, Basha NA, et al (2022) Development and validation of standardized severity rating scale to assess the consistency of drug-drug interaction severity among various drug information resources. Research in Social and Administrative Pharmacy 18(8):3323--3328

    2022

  54. [62]

    IEEE Transactions on Knowledge and Data Engineering 25(1):158--176

    Shvaiko P, Euzenat J (2013) Ontology matching: state of the art and future challenges. IEEE Transactions on Knowledge and Data Engineering 25(1):158--176. doi:10.1109/TKDE.2011.253

    2013 doi

  55. [63]

    Nucleic acids research 51(D1):D977--D985

    Sollis E, Mosaku A, Abid A, et al (2023) The NHGRI-EBI GWAS catalog: knowledgebase and deposition resource. Nucleic acids research 51(D1):D977--D985

    2023

  56. [64]

    Journal of Management 50(2):123--145

    Stevenson R, Fisher G, D'Souza R (2024) The minimum viable product (mvp): Theory and practice. Journal of Management 50(2):123--145. doi:10.1177/01492063241227154

    2024 doi

  57. [65]

    Health Information & Libraries Journal 40(2):125--168

    Tan YXF, Lim STY, Lim JL, et al (2023) Drug information-seeking behaviours of physicians, nurses and pharmacists: A systematic literature review. Health Information & Libraries Journal 40(2):125--168

    2023

  58. [66]

    Nucleic Acids Research 51(D1):D523--D531

    The UniProt Consortium (2023) Uniprot: the universal protein knowledgebase in 2023. Nucleic Acids Research 51(D1):D523--D531

    2023

  59. [67]

    National Library of Medicine (2023) MEDLINE : Bibliographic database of life sciences and biomedical information

    U.S. National Library of Medicine (2023) MEDLINE : Bibliographic database of life sciences and biomedical information. https://www.nlm.nih.gov/medline/, accessed April 2025

    2023

  60. [68]

    National Library of Medicine (2025) DailyMed: Current Medication Information

    U.S. National Library of Medicine (2025) DailyMed: Current Medication Information . https://dailymed.nlm.nih.gov/, accessed April 2025

    2025

  61. [69]

    Scientific data 3:160018

    Wilkinson MD, Dumontier M, Aalbersberg IJ, et al (2016) The FAIR Guiding Principles for scientific data management and stewardship . Scientific data 3:160018

    2016

  62. [70]

    Nucleic Acids Research 51(D1):D1144--D1154

    Wishart DS, Feunang YD, Guo AC, et al (2023) DrugBank 2023: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Research 51(D1):D1144--D1154. doi:10.1093/nar/gkac1077, ://go.drugbank.com/

    2023 doi

  63. [71]

    https://www.uptodate.com/, accessed April 10, 2025

    Wolters Kluwer (2024) UpToDate Clinical Decision Support . https://www.uptodate.com/, accessed April 10, 2025

    2024

  64. [72]

    Scientific Data 7(1):205

    Xu J, Kim S, Song M, et al (2020) Building a PubMed knowledge graph . Scientific Data 7(1):205

    2020

  65. [73]

    In: Proceedings of the 27th European Conference on Artificial Intelligence (ECAI 2024)

    Yan X, Westphal P, Seliger J, et al (2024) Bridging the gap: Generating a comprehensive biomedical knowledge graph question answering dataset ( PrimeKGQA ). In: Proceedings of the 27th European Conference on Artificial Intelligence (ECAI 2024). IOS Press, pp 1198--1205, doi:10...

    2024 doi

  66. [74]

    Briefings in bioinformatics 22(4):bbaa344

    Zheng S, Rao J, Song Y, et al (2021) PharmKG : a dedicated knowledge graph benchmark for bomedical data mining. Briefings in bioinformatics 22(4):bbaa344

    2021

  67. [75]

    Journal of Biomedical Semantics 11(1):1--12

    Zhu Q, Nguyen DT, Grishagin I, et al (2020) An integrative knowledge graph for rare diseases, derived from the genetic and rare diseases information center ( GARD ). Journal of Biomedical Semantics 11(1):1--12. doi:10.1186/s13326-020-00232-y

    2020 doi

  68. [76]

    Bioinformatics 34(13):i457--i466

    Zitnik M, Agrawal M, Leskovec J (2018) Modeling polypharmacy side effects with graph convolutional networks. Bioinformatics 34(13):i457--i466

    2018

  69. [77]

    , " * write output.state after.block = add.period write newline

    ENTRY address archive author booktitle chapter doi edition editor eid eprint howpublished institution journal key keywords month note number organization pages publisher school series title type url volume year archivePrefix primaryClass adsurl adsnote version label extra.labe...

  70. [78]

    write newline

    " write newline "" before.all 'output.state := FUNCTION add.period duplicate empty 'skip "." * add.blank if FUNCTION if.digit duplicate "0" = swap duplicate "1" = swap duplicate "2" = swap duplicate "3" = swap duplicate "4" = swap duplicate "5" = swap duplicate "6" = swap dupl...

Pith tools

Reviewed August 15, 2026 · model on record in the stance chip above.